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Abstract 
Background 
Artificial intelligence (AI) systems performing at radiologist-like levels in the evaluation of 
digital mammography (DM) would improve breast cancer screening accuracy and efficiency. 
We aimed to compare the stand-alone performance of an AI system to that of radiologists 
in detecting breast cancer in DM. 
Methods 
Nine multi-reader multi-case study datasets previously used for different research purposes 
in seven countries were collected. Each dataset consisted of DM exams acquired with 
systems from four different vendors, multiple radiologists’ assessments per exam, and 
ground truth verified by histopathological analysis or follow-up, yielding a total of 2,652 
exams (653 malignant) and interpretations by 101 radiologists (28,296 independent 
interpretations). An AI system analyzed these exams yielding a level of suspicion of cancer 
present between 1 and 10. The detection performance between the radiologists and the AI 
system was compared using a non-inferiority null hypothesis at a margin of 0.05. 
Results 
The performance of the AI system was statistically non-inferior to that of the average of the 
101 radiologists. The AI system had a 0.840 (95% CI = 0.820-0.860) area under the ROC curve 
(AUC) while the average of the radiologists was 0.814 (95% CI = 0.787-0.841) (difference 
95% CI = (-0.003-0.055)). The AI system had an AUC higher than 61.4% of the radiologists.  
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Conclusions  The evaluated AI system achieved a cancer detection accuracy comparable to 
an average breast radiologist in this retrospective setting. While promising, the 
performance and impact of such a system in a screening setting needs further investigation. 
 
 
Keywords Mammography, artificial intelligence, breast cancer, computer detection 
systems, deep learning 
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Introduction 
Breast cancer is the most common cancer in women, and despite important 
improvements in therapy, it is still a major cause for cancer-related mortality, accounting 
for approximately 500,000 annual deaths worldwide1. Population-based breast cancer 
screening programs using mammography are regarded as effective in reducing breast 
cancer-related mortality 2-5. However, current screening programs are highly labor intensive 
due to the large number of women screened per detected cancer, and the use of double 
reading, especially in European screening programs, which also leads to additional 
economical costs. Moreover, despite this practice up to 25% of mammographically-visible 
cancers are still not detected at screening 6-9. 
Considering the increasing scarcity of radiologists in some countries, including 
breast screening radiologists 10-12, alternative strategies to allow continuation of current 
screening programs are required. In addition, it is of paramount importance to prevent 
visible lesions in digital mammography (DM) being overlooked or misinterpreted. 
Since the 1990s, computer-aided detection (CAD) systems have been developed to 
automatically detect and classify breast lesions in mammograms. The widespread 
implementation of DM for breast cancer imaging further spurred the development of 
automated detection techniques for breast cancer. Unfortunately, no studies to date have 
found that traditional CAD systems directly improve screening performance or cost-
effectiveness, mainly because of a low specificity 13,14. This has also precluded their use as 
a stand-alone reader for screening mammography.  
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However, the field of artificial intelligence (AI) is rapidly changing due to the success 
of novel algorithms based on deep learning convolutional neural networks. These 
approaches are very successful in automating cognitively difficult tasks; classic examples 
include self-driving cars and advanced speech recognition. In medical imaging, deep 
learning-based AI is also rapidly closing the gap between humans and computers 15,16. It has 
been suggested that such algorithms could therefore have the potential to further improve 
the benefit-harm-ratio  of breast cancer screening programs 17. In recent years, several deep 
learning-based algorithms for automated analysis of mammograms have been developed, 
some of which have already shown very promising results when compared to radiologists, 
but in very limited and homogeneous scenarios 18,19. 
Therefore, in this study, we compare, at a case level, the cancer detection 
performance of a commercially available AI system to that of 101 radiologists who scored 
nine different cohorts of DM examinations from four different manufacturers as part of 
reader studies previously performed for other purposes.  
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Methods 
Artificial intelligence system 
In this study we used an AI system for breast cancer detection in DM and digital 
breast tomosynthesis (Transpara 1.4.0, Screenpoint Medical BV, Nijmegen, The 
Netherlands). The system uses deep learning convolutional neural networks, feature 
classifiers and image analysis algorithms to detect calcifications20,21 and soft tissue lesions22-
24 in two different modules. For each exam, on the basis of the individually-classified 
suspicious findings, the system provides a continuous score ranging between 1 and 10 
representing the level of suspicion of cancer present (where 10 represents highly suspicious 
of malignancy present). This system can be applied to processed (i.e. “for presentation”) 
DM images from multiple vendors and makes use of both the mediolateral oblique and 
cranio-caudal views of each breast. However, the AI system does not use information from 
prior mammograms (when available).  
The AI system is trained, validated, and tested using a database containing over 
9,000 mammograms with cancer (one third of which are presented as lesions with 
calcifications) and 180,000 mammograms without abnormalities. The mammograms 
originate from devices from four different vendors (Hologic; Siemens; General Electric, 
Waukesha, WI; Philips, Eindhoven, The Netherlands) and institutions across Europe, United 
States and Asia. The AI system is independently tested with exams never used for training 
or validation of the algorithms. The mammograms used in this study have never been used 
to train, validate or test the algorithms. 
Digital Mammograms 
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We collected sets of DM examinations that were read by multiple radiologists during 
other unrelated, and previously completed, retrospective multi-reader multi-case (MRMC) 
observer studies 25-32. In those studies, DM was compared to another modality (e.g. digital 
breast tomosynthesis) for breast cancer detection in cancer-enriched datasets. In total, nine 
distinct DM datasets were obtained from different institutions across Europe and the 
United States (Table 1).  The review board at each institution waived local ethical approval 
and informed consent or directly approved the use of the anonymized patient data for 
retrospective research.  
Each dataset consisted of three items: DM exams, the radiologists’ scores of each 
DM exam, and their ground truth. DM exams were processed “for presentation” 2D images, 
two views per breast (CC and MLO) that could be unilateral or bilateral The corresponding 
radiologists’ scores for each DM exam were in the form of forced Breast Imaging Reporting 
and Data System (BI-RADS®) scores (scale 1-5; 1 = negative, 2 = benign findings, 3 = probably 
benign, 4 = suspicious abnormality, 5 = highly suspicious of malignancy) and/or probability 
of malignancy (PoM) scores (scale 1-100). All interpretations involved single reading by 
individual radiologists, differing from standard practice in many screening programs, which 
use double reading plus consensus or arbitration. Finally, the ground truth was defined in 
terms of cancer present or absent, of each DM exam, confirmed by histopathology and/or 
at least one year of follow-up. 
In all datasets, the radiologists individually scored each DM exam, without time 
constraint, and without access to other imaging techniques or any AI systems. There were 
differences across datasets (see Table 1) regarding study population and reading workflow. 
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Also, for some datasets, the radiologists had access to priors (not processed by this version 
of this AI system). In total, 28,296 independent exam interpretations of 2,652 cases were 
collected. Differences in numbers between the original study populations and the included 
populations are due to images and/or readings lost during data archiving at the original 
institutions (n = 13) as well as problems during processing with the AI system (n = 7, e.g., 
because the case contained implants). 
Table 1 shows the distributions of the radiologists’ experience with mammography 
for each dataset, which resembles the heterogeneous distribution seen in practice, as 
reported in the original publications. Readers from the United States were MQSA-qualified 
(Mammography Quality Standards Act), and included an approximately even mix of general 
and breast-specialized radiologists, while all the readers from Europe were specialized in 
breast imaging and were qualified according to the European guidelines for quality 
assurance in breast cancer screening 33.  For their studies, they were instructed to score 
simulating a screening practice.  
Statistical analysis 
The accuracy of the radiologists was compared to that of the AI system with a non-
inferiority null-hypothesis based on differences in the area under the receiver operating 
characteristic curve (AUC). Only cases with malignant lesions were considered positive. 
Since this AI system had not been tested before, we did not assume a performance level 
pre-study, and hence did not calculate the power of this study. Instead, the study was 
performed with as much data as could be gathered to have the most robust conclusion 
possible. 
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Non-inferiority testing 
Non-inferiority analysis 34-38 was used to compare the AI system to the radiologists. 
The non-inferiority margin was set at 0.05, since it was considered that differences below 
this margin are clinically unimportant. Non-inferiority was concluded if the AUC difference 
AI-radiologists was greater than 0 and the lower limit of the 95% confidence interval (CI) of 
the difference was greater than the negative value of the non-inferiority margin (-0.05). 
Primary endpoint: Overall AUC performance of the AI system vs. 101 radiologists 
We pooled the datasets listed in Table 1 and compared the reader-averaged AUC 
against the AUC of the AI system. The public-domain iMRMC software (version 4.0.0, 
Division of Imaging, Diagnostics, and Software Reliability, OSEL/CDRH/FDA, Silver Spring, 
MD) 36,37 was used, which can handle arbitrary (not fully-crossed) study designs, including 
the split-plot design resulting when pooling datasets as in this study 39,40. The software 
expects multiple readers but can treat a single reader (the AI system) if the data is formatted 
properly. The iMRMC software can also handle the mixed scoring scales in the different 
datasets since the scores from different readers are never compared. If probability of 
malignancy was available, it was preferred over BI-RADS as it better samples the receiver 
operating characteristic (ROC) space and it is an ordinal scale 41. For the AI system, its scoring 
exam-based scale (1-10) was used for ROC analysis. We created reader-averaged ROC 
curves by averaging the reader-specific non-parametric (trapezoidal) curves along lines 
perpendicular to the chance line 42. This average is area-preserving; its AUC is equal to the 
reader-averaged non-parametric AUCs.  
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The analysis of the MRMC data, which yielded the empirical AUC values and their 
95% CI, were computed following U-statistics to provide unbiased estimates of the variance 
components36,43. In this way, the total variance is decomposed into eight moments from 
first principles (similar to U-statistics), considering non-diseased cases separately from 
diseased cases so that the total variance can be easily generalized to new readers, new non-
diseased cases, and new diseased cases. 
Secondary endpoints: performance comparisons for each dataset 
As secondary endpoints, the AUC and operating points were compared between the 
AI system and the average of radiologists for each dataset and against each individual 
radiologist. The reported 95% CI are not adjusted for testing multiple hypotheses, since the 
high amount of multiple comparisons (N=215) would make statistical testing impractical. 
Instead, this analysis is meant to be descriptive and to identify any possible outliers in the 
datasets. 
Standard MRMC analysis of variance was used to compare the AUC between the AI 
system and the average of radiologists, based on the methods by Gallas et al. implemented 
in iMRMC 36,37. Similarly, as with the split-plot analysis defined above, the AI system was 
defined as an independent second modality. 
The sensitivity at the radiologists’ specificity was compared between the radiologists 
and the AI system as determined by a screening scenario threshold (BI-RADS 3 or higher 
was considered positive, while in dataset C, radiologists directly indicated whether the case 
was recalled or not). There was no recall information for Dataset B, which involved 6 
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radiologists, (the original study did not ask radiologists for a recall decision) and therefore 
it was not included in this analysis. Consequently, sensitivity could therefore only be 
computed for 95 radiologists. The average sensitivity and specificity of the radiologists were 
computed with iMRMC using a single-modality analysis of variance with dichotomized 
scores as input. For the AI system, the operating point of the ROC that was closest to the 
average radiologist’s specificity was then selected to dichotomize the results. Radiologists 
and AI system sensitivities were compared with iMRMC using a standard MRMC two-
modality analysis of variance at the same specificity level.  
 
Results  
Overall AUC performance: AI system vs. 101 radiologists 
The AUC of the AI system (0.840, 95% CI = 0.820-0.860) was statistically non-inferior 
to that of the 101 radiologists (0.814, 95% CI = 0.787-0.841). The AUC difference was 0.026 
(95% CI = -0.003, 0.055), slightly higher for the AI system at the range of low- and mid- 
specificity. The average ROC curves are displayed in Figure 1. 
The system had a higher AUC than 62/101 radiologists (61.4%, Figure 2) and higher 
sensitivity than 55/95 radiologists (57.9%, Figure 3), but its performance was always lower 
than that of the best radiologist (Supplementary Table 1).  
 
Performance comparisons for each dataset  
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For each dataset, the AUC and sensitivity of the AI system was similar to that of the average 
of the radiologists, and no outliers were identified (Supplementary Tables 1 and 2). 
Absolute differences (AUC AI system – AUC average of radiologists) varied between -0.008 
and +0.038 per dataset (Supplementary Table 1). The ROC curve of the AI system is plotted 
against the radiologists’ ROC curves in Supplementary Figure 1. 
The average operating point of the radiologists was different across datasets, with 
specificities ranging from 0.49 to 0.79, and sensitivities between 0.76 and 0.84 (see 
Supplementary Table 2 and Supplementary Figure 1). At the average specificity of the 
radiologists, the AI system had a higher sensitivity in 5 out of 8 datasets (1.0-8.0%), and 
lower in 3 datasets (1.0-2.0%).  
 
Discussion 
Our results clearly show that recent advances in AI algorithms have narrowed the 
gap between computers and human experts in detecting breast cancer in digital 
mammograms. Nevertheless, the performance of AI was consistently lower than the best 
radiologists in all datasets.  The large and heterogeneous population of cases used in this 
study shows that our findings might hold true across different lesion types, mammography 
systems and country-specific practices.   
Across the collected data, differences were seen in the performance of the readers. 
As expected, readings in the United States had a lower average specificity than those in 
Europe, where screening recall rates are lower 44. For Dataset A, even though performed in 
Europe, the average specificity is similar to North-American readings. Perhaps this is 
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explained by the dataset being mostly composed of breasts with high density, which might 
have made radiologists modify their operating points. The wide range in average AUC values 
(0.769 – 0.907) across datasets shows that the difficulty of the populations varied 
substantially, due to, for instance, inclusion of specific lesion types, different proportions of 
enrichments, or availability of prior exams and/or exams of the contralateral breast. It 
should be noted that the AUC values for the radiologists were lower than those reported in 
US clinical practice by the Breast Cancer Surveillance Consortium, which are above 0.90 45. 
This is likely because the datasets used in this study were highly enriched with cancers and 
false positive exams, resulting in a case set which is substantially more challenging than a 
screening mammography set. 
For the AI system, the performance was very close to the average of radiologists in 
all datasets. Interestingly, this also held in all datasets (Dataset B, C, D) where the AI system 
had the disadvantage of not considering information from the prior mammograms, whereas 
the radiologists had access to available prior images. The reader-averaged ROC curve of the 
101 radiologists was almost identical to that of the AI system at high specificity, while the 
AI system showed slightly higher AUC at mid and low specificity. Since this data was 
enriched with cancer and benign lesions, the screening recall operating point of radiologists 
lied at the mid-range in specificity. At this fixed recall specificity, the AI system achieved 
higher sensitivity than a majority of the radiologists.  
However, given the fact that this database was not prospectively defined for this 
study, caution should be taken in interpreting the results. In particular, although most 
exams in the original studies are from screening, and all radiologists were instructed to 
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score simulating a screening practice, the main limitation of this study is that it was based 
on retrospective reader studies of enriched case sets. Therefore, the human performance 
was affected by a “laboratory effect” that reflects the reading of enriched datasets 46,47. 
Since the main application of such an AI system would be a screening setting, the stand-
alone performance of the AI system on actual screening data should be studied, including 
the distribution of lesions seen in screening, and comparing it to the radiologists’ 
performance during actual screening interpretation. Collecting such a high number of 
cancer cases and prospective readings from a similarly large number of radiologists in an 
actual screening scenario, would be notably challenging, however, requiring the 
collaboration of a very large number of centers. 
Even if the AI system performed comparably to the human radiologists, there is still 
room for improvement. There is no a priori reason why the AI system should not be 
performing, at least, as the best radiologist. In our study, the AI system had an AUC lower 
than the best radiologist in every dataset. This could be explained by the fact that 
radiologists interpret more information (e.g. comparisons with prior exams and 
contralateral breasts) than this version of this AI system. An ideal AI system should be able 
to perform up to the limitations of the imaging modality itself; in other words, be only 
incapable of detecting mammographically occult cancers, while minimizing false positive 
findings. Determining the trade-off between cancer detection and assessment of false 
positive findings would then be the only human choice involved. However, to achieve a 
higher-than-human performance, the training of the AI systems might need to not be based 
on truth as established by humans. 
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Future work, not assessed in our study due to lack of information from the original 
studies, is to analyze the AI system performance per lesion type, tumor characteristics, or 
lesion location. For instance, evaluation of the sensitivity as a function of false positive 
findings, taking localization into account (i.e., using free receiver operating characteristic 
analysis) should could be of interest, especially in order to verify the potential of using such 
an AI system as a reader aid rather than as a stand-alone reader. Moreover, although most 
cases were collected from screening examinations, a limitation is that we cannot know 
exactly how representative of an actual screening population our dataset is, in terms of 
tumor size and types, since these characteristics were not reported in the original study 
publications. Similarly, it is unknown whether the better performing radiologists were the 
radiologists with the most experience, as the original studies did not report the individual 
experience of each radiologist. Consequently, we cannot assess whether the AI system 
performs better or worse than radiologists as a function of the experience of the latter. 
However, the heterogeneity of experience seen in our data is representative of that seen in 
screening practice. Consequently, we can conclude that the AI system is as good as an 
average screening radiologist. 
Artificial intelligence that functions at the level of an expert radiologist for breast 
cancer detection in DM images might herald a change in the breast healthcare workflow, 
whether in a screening or in a clinical setting. Yet we still need to determine the optimal 
integration of such a system in the breast care pathway, prior to assessing the final impact 
that this type of AI technology can have on patient care.  
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In a population-based screening setting, the possibilities of workflow enhancement 
via implementation of an AI system are ample. One of the biggest potential benefits lies in 
the possibility of using such a system in countries where there is a lack of experienced breast 
radiologists, which might, for instance, impede the development, expansion, or 
continuation of screening programs. In these situations, AI could be used as an independent 
stand-alone first or second reader 48.  
In parallel, it could also be used as an interactive decision support tool 27, pointing 
out potential lesions, preventing overlook and interpretation errors that are relatively 
common in the reading of DM 6-9. However, for this aspect, the impact of automation bias 
in decision making should be addressed. Furthermore, it is well known that the very low 
prevalence of breast cancer in the screening population reduces the performance of 
radiologists, increasing the risk of false negatives 47,49. An AI system tuned to achieve high 
sensitivity could be used to automatically discard a significant amount of DM exams which 
are most likely normal, reducing the workload and resulting in a case set with a higher 
prevalence of cancer for radiologists to read. The higher sensitivity of the AI system at low 
specificity found in this study points to the feasibility of this scenario. However, the 
drawbacks of introducing AI, especially as stand-alone readers, have to be studied. 
Regulations to define the medicolegal consequences when AI fails would have to be 
established. Equally, trade-offs between patient outcome and cost-effectiveness have to be 
carefully addressed.  
In conclusion, the tested AI system based on deep learning algorithms has similar 
performance as an average radiologist for detecting breast cancer in mammography. These 
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results were consistently observed across a large heterogeneous multi-center multi-vendor 
cancer-enriched cohort of mammograms. While promising, the performance and the 
fashion of implementation of such an AI system in a screening setting remains to be further 
investigated. 
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Table 
Table 1. Details of each dataset collected for this study.  
Dataset Reference 
Reading 
Country 
Vendor(s) 
Case set 
population  
Exam 
type 
Total no. 
of exams 
Exam result, No. 
No. of 
Radiologists 
Radiologists 
Experience, 
y 
Score 
scale 
Cancer 
Benign 
lesions 
Normal 
A 25 
 
 
Wallis et al, 2012 25 
Sweden, UK GE 
Sectra 
40-80 (avg.=56) 
years old 
Screening (n=86) 
+ Clinical (n=43) 
Only BI-RADS 
density >2 
Bilateral 
no priors 
129 40 23 66 14 3-25 
(avgerage= 
10) 
BI-RADS 
B 26 
 
Visser et al, 2012,26 Netherlands GE 51-86 (avg.=60) 
years old 
Screening 
Bilateral 
+ priors 
263 43 110 110 6 1-34 PoM* 
C 27 
 
Hupse et al, 201327 Netherlands Hologic 50-74 years old 
Screening 
Bilateral 
+ priors 
199 79 20 100 9 1-24 
(average = 
14) 
PoM† 
D 28 
 
Gennaro et al, 201328 Italy GE >40 years old 
Clinical 
 
Unilateral 
+ priors 
469 68 200 201 6 5-30 BI-RADS 
E1 29 
 
Siemens Medical Solutions, 
201529 
US GE 
Siemens 
Hologic 
>40 years old 
Screening + 
Clinical 
Bilateral 
no priors 
298‡ 49 84 165 22 > 5 PoM 
BI-RADS 
E2 29 
 
Siemens Medical Solutions, 
201529 
US GE 
Siemens 
Hologic 
>40 years old 
Screening + 
Clinical 
Bilateral 
no priors 
326‡ 104 79 143 31 > 5 PoM 
BI-RADS 
27 
 
F 30 
 
Garayoa et al, 2018 30 Spain Hologic 34-92 (avg.=55) 
years old 
Screening 
+ Clinical 
Unilateral 
no priors 
585 113 160 313 3 10-20 BI-RADS 
G 31 
 
Rodriguez-Ruiz et al, 2018 31 Netherlands 
Sweden 
Siemens 30-88 (avg.=52) 
years old 
Screening (n=60) 
+ Clinical (n=121) 
 
Unilateral 
no priors 
179 75 49 55 6 3-44 
(average = 
22) 
PoM 
BI-RADS 
H 32 
 
Clauser et al, 2018, 32 Austria Siemens 36-84 (avg.=56) 
years old 
Screening 
+ Clinical 
Bilateral 
no priors 
204 82 43 80 4 > 5 BI-RADS 
TOTAL - 7 countries 4 vendors - - 2652 653 
(24.6%) 
768 (29.0%) 1233 
(46.4%) 
101 - - 
* No BI-RADS scores were used in this study, and radiologists were not asked to decide on recall/no recall. PoM = Probability of 
malignancy (1-100); avg. = average. BI-RADS: Breast Imaging Reporting and Data System scores (1-5). 
DM manufacturers listed: Sectra Mamea, Solna, Sweden; Siemens Healthineers, Forcheim, Germany; Hologic Inc, Bedford, MA, USA; 
General Electric Healthcare, Waukesha, WI, USA 
† No BI-RADS scores were used in this study, but radiologists were asked to decide on recall/no recall 
‡ The cases from these two datasets overlap and come from a unique population of 425 DM exams (107 malignant, 102 benign, 216 
normal). The radiologists are different. 
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Figures 
 
Figure 1. Receiver operating characteristic (ROC) curve comparison between the reader-
averaged radiologists and the artificial intelligence (AI) system in terms of area under the 
curve (AUC). Parentheses show the 95% confidence interval of the AUC.  
 
Figure 2. Differences in area under the receiver operating characteristic curve (AUC) 
between the artificial intelligence (AI) system and each radiologist.  
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Figure 3. Differences (%) in sensitivity between the artificial intelligence (AI) system and 
each radiologist, at the specificity of each radiologist considering BI-RADS ≥3 as positive 
recall. BI-RADS = Breast Imaging Reporting and Data System.  
